These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29339440)

  • 1. Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer.
    Muliaditan T; Opzoomer JW; Caron J; Okesola M; Kosti P; Lall S; Van Hemelrijck M; Dazzi F; Tutt A; Grigoriadis A; Gillett CE; Madden SF; Burchell JM; Kordasti S; Diebold SS; Spicer JF; Arnold JN
    Clin Cancer Res; 2018 Apr; 24(7):1617-1628. PubMed ID: 29339440
    [No Abstract]   [Full Text] [Related]  

  • 2. The effectiveness of oral tin mesoporphyrin prophylaxis in reducing bilirubin production after an oral heme load in a transgenic mouse model.
    DeSandre GH; Wong RJ; Morioka I; Contag CH; Stevenson DK
    Biol Neonate; 2006; 89(3):139-46. PubMed ID: 16205054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems.
    Sorrenti V; D'Amico AG; Barbagallo I; Consoli V; Grosso S; Vanella L
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34205698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
    Bartkowiak T; Jaiswal AR; Ager CR; Chin R; Chen CH; Budhani P; Ai M; Reilley MJ; Sebastian MM; Hong DS; Curran MA
    Clin Cancer Res; 2018 Mar; 24(5):1138-1151. PubMed ID: 29301830
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic effects of orally-administered zinc and tin (IV) metalloporphyrins on heme oxygenase expression in mice.
    Morioka I; Wong RJ; Abate A; Vreman HJ; Contag CH; Stevenson DK
    Pediatr Res; 2006 May; 59(5):667-72. PubMed ID: 16627879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression, function and targeting of haem oxygenase-1 in cancer.
    Hjortsø MD; Andersen MH
    Curr Cancer Drug Targets; 2014; 14(4):337-47. PubMed ID: 24655000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of Bach1 in the induction of heme oxygenase by tin mesoporphyrin.
    Abate A; Zhao H; Wong RJ; Stevenson DK
    Biochem Biophys Res Commun; 2007 Mar; 354(3):757-63. PubMed ID: 17257585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages.
    Kim SH; Saeidi S; Zhong X; Gwak SY; Muna IA; Park SA; Kim SH; Na HK; Joe Y; Chung HT; Kim KE; Han W; Surh YJ
    Neoplasia; 2020 Nov; 22(11):606-616. PubMed ID: 33039895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
    Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
    Cui S
    Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.